--- title: "14:43 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON" type: "News" locale: "en" url: "https://longbridge.com/en/news/285421981.md" description: "Rosen Law Firm is investigating potential securities claims for shareholders of Disc Medicine, Inc. (NASDAQ: IRON) due to allegations of misleading business information. Investors who purchased Disc Medicine securities may be entitled to compensation through a class action lawsuit. This follows a 22% stock price drop after the FDA issued a Complete Response Letter regarding Disc Medicine's new drug application. The firm has a strong track record in securities class actions and encourages investors to choose qualified legal counsel." datetime: "2026-05-06T18:43:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285421981.md) - [en](https://longbridge.com/en/news/285421981.md) - [zh-HK](https://longbridge.com/zh-HK/news/285421981.md) --- # 14:43 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case\_id=56641 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email \[email protected\] for information on the class action. What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA that would need additional evidence. On this news, Disc Medicine's stock price fell 22% on February 13, 2026. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 \[email protected\] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. ### Related Stocks - [IRON.US](https://longbridge.com/en/quote/IRON.US.md) ## Related News & Research - [22:10 ETRosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON](https://longbridge.com/en/news/286022909.md) - [Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)](https://longbridge.com/en/news/285910632.md) - [17:28 ETRosen Law Firm Encourages FLOW Cryptocurrency Investors to Inquire About Securities Class Action Investigation](https://longbridge.com/en/news/286821600.md) - [Disc Medicine (IRON) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/284706493.md) - [ISC Reports Financial Results for the First Quarter of 2026](https://longbridge.com/en/news/286625046.md)